drugset / Trial / NCT03956212

Inflammatory Mediators in Erythema Migrans

NCT03956212

NaSingle-groupOpen-labelBasic science

Summary

The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that could serve as biomarkers of disease activity.

Timeline

Start
2017-06-01
Primary completion
2019-12-31
Completion
2020-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 100 mg Oral

Indications

No indication recorded.